1. Name of product
2. Potential advantages
1) More active than any other Quinolones (in vitro, in vivo)
2) Highly active against respiratory tract pathogen (G(+) - S.pneumoniae, S.aureus, S.pyogenes and M.catarrhalis)
3) Good safety profile (in mouse, rat and dog)
4) No phototoxicity
New fluoroquinolone antimicrobial agents(Zabofloxacin, DW224) has broad antibacterial activities. It has also excellent activities against RTI pathogen. In preclinical and clinical studies, it has established a good safety profile.
Final stage of phase III clinical trial